Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University Hospital, Gentofte, Copenhagen
Modality
protein_peptide
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07506369CT.gov Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans | — | Recruiting | — | — | — |
NCT06619015CT.gov Tailoring Obesity Treatment Trial | — | Withdrawn | — | — | — |
NCT01235741CT.gov A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects | — | Terminated | — | — | — |
NCT00819234CT.gov Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin | — | Completed | — | — | — |
NCT00673387CT.gov Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | — | Completed | — | — | — |
NCT00402077CT.gov A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | — | Completed | — | — | — |
NCT00392925CT.gov A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects | — | Completed | — | — | — |
NCT00691158CT.gov A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide | — | Unknown | — | — | — |
NCT00189514CT.gov A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects | — | Completed | — | — | — |
NCT00112021CT.gov A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00444561CT.gov Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tripro-Amylin (this asset) | University Hospital, Gentofte, Copenhagen | P2/3 | BB · 65 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Tripro-Amylin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BB · 65 |
| Schizoaffective Disorder | — | P4 | BB · 65 |
| Schizophrenia | — | P4 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tripro-Amylin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tripro-amylin-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →